IDEAYA Biosciences, Inc.·4

May 28, 9:14 PM ET

DIEKMAN JOHN D 4

4 · IDEAYA Biosciences, Inc. · Filed May 28, 2019

Insider Transaction Report

Form 4
Period: 2019-05-28
Transactions
  • Conversion

    Common Stock

    2019-05-28+578,4472,604,545 total(indirect: See footnote)
  • Conversion

    Common Stock

    2019-05-28+24,101108,521 total(indirect: See footnote)
  • Purchase

    Common Stock

    2019-05-28$10.00/sh+240,000$2,400,0002,844,545 total(indirect: See footnote)
  • Conversion

    Series A Preferred Stock

    2019-05-281,721,8980 total(indirect: See footnote)
    Common Stock (1,721,898 underlying)
  • Conversion

    Series A Preferred Stock

    2019-05-2871,7450 total(indirect: See footnote)
    Common Stock (71,745 underlying)
  • Conversion

    Common Stock

    2019-05-28+1,721,8982,026,098 total(indirect: See footnote)
  • Conversion

    Common Stock

    2019-05-28+71,74584,420 total(indirect: See footnote)
  • Purchase

    Common Stock

    2019-05-28$10.00/sh+10,000$100,000118,521 total(indirect: See footnote)
  • Conversion

    Series B Preferred Stock

    2019-05-28578,4470 total(indirect: See footnote)
    Common Stock (578,447 underlying)
  • Conversion

    Series B Preferred Stock

    2019-05-2824,1010 total(indirect: See footnote)
    Common Stock (24,101 underlying)
Footnotes (5)
  • [F1]Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.
  • [F2]Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.
  • [F3]The shares are held by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV. Dr. Diekman disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
  • [F4]Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.
  • [F5]The shares are held by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Dr. Diekman disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Documents

1 file
  • 4
    doc1.xmlPrimary

    FORM 4